RDIF announces strategic partnership in digital medical services between its portfolio company Doctis and Mail.ru Group
Moscow, June 5, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, today announces a strategic partnership between its portfolio company Doctis and Mail.ru Group, Russia’s leading internet and IT-company.
Using Artificial Intelligence (AI) technology and further expanding its remote medical services, Doctis is set, with the support of RDIF, to deliver major growth, increasing the volume of online consultations to 100,000 per week and the number of users to 5 million by the end of 2020.
At the initial stage of the partnership Doctis will integrate its services into the “Health Mail.ru” website. This will enable users to receive online consultations from doctors at leading Russian clinics, including MD Medical Group, MMC SOGAZ, United Medical Systems Group of Companies and others in addition to the website’s existing information services. The agreement with Mail.ru Group will enable Doctis’ to provide high-quality telemedicine services to even more users and support the further growth of the company.
Since March this year the number of calls to Doctis and consultations by its medical specialists conducted via the platform have increased more than 20 times. The retail segment has demonstrated an unprecedented 500-fold increase in revenue. The number of medical specialists providing consultations via Doctis has increased more than 10 times. Since the beginning of the year, more than 130 clinics have become partners of the service with the total number of partner clinics now exceeding 530. Russia’s largest banks and corporations are also actively cooperating with the service.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:
“Remote technologies make it possible to successfully respond to many challenges arising as the result of the COVID-19 outbreak. As the health of the public is one of the main state priorities, the development of telemedicine is becoming a common goal. RDIF and Doctis are convinced that demand for telemedicine will remain high not only during the pandemic but in the long term. Partnership with Mail.ru Group in a market that will soon reach 100 million people, will enable Doctis to quickly scale up its service, while maintaining high quality and ensuring the implementation of the most advanced technologies.”
Mark Kurtser, founder of Doctis, CEO of MD Medical Group, noted:
“The Doctis telemedicine service is a convenient tool for health monitoring and solving a range of medical problems for patients regardless of where they live across Russia. Currently, more than 1,200 doctors of MD Medical Group and other leading clinics provide medical advice remotely via the service. In addition, the AI-based “Virtual Doctor” helps users comply with preventive measures during the pandemic and enables them to receive answers to coronavirus-related questions online without breaching the self-isolation regime.”
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB1.8 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 15 countries that total more than $40 bn.
RDIF takes active steps to counteract COVID-19:
- RDIF and partners have launched the production of the unique Russian-Japanese EMG diagnostic system, which generates results in 30 minutes with a very high accuracy in both stationary and unmatched portable mini-laboratories. The Japan Bank for International Cooperation has joined the project through the Russia-Japan Investment Fund;
- RDIF and the ChemRar Group have started the mass-scale production of Avifavir, which has proven effective against coronavirus in clinical trials and received a registration certificate from the Ministry of Health of the Russian Federation;
- RDIF has launched a project to diagnose and detect pneumonia, including that caused by coronavirus, using CT scans combined with the Russian-UAE artificial intelligence (AI) technology developed jointly by Group 42 (G42), RDIF and Medscan Group;
- RDIF has provided support to the public in observing the lockdown restrictions and self-isolation regime, driving a several-fold increase in telemedicine consultations via the Doctis service, as well as in access and subscriptions to the ivi online media library, delivery of Elementaree meal kits and demand for products and services of other RDIF portfolio companies;
- The Mother and Child Group, an RDIF's portfolio company, has repurposed its largest clinical hospital Lapino to treat patients with COVID-19 symptoms.
- RDIF was one of the initiators of the Alliance against coronavirus, which also includes the Russian Union of Industrialists and Entrepreneurs (RUIE), Yandex, Mail.ru Group and the Rossiya Segodnya international news agency. RDIF is actively involved in key initiatives and charity projects.
Further information can be found at rdif.ru
Doctis is a multifunctional healthcare online platform. It operates an online medical centre that allows patients to comprehensively evaluate and track their health. It partners with the state and private clinics and experts to provide services based on user's personal medical data, utilizing a single online medical data storage system, which includes medical records of all family members. www.doctis.ru
For additional information contact:
Russian Direct Investment Fund
Tel: +7 495 644 34 14, ext. 2395
Mobile: +7 916 110 31 41
Andrew Leach / Maria Shiryaevskaya
Tel: +44 (0) 20 7796 4133
Tel: +7 925 347 83 81